Profile data is unavailable for this security.
About the company
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
- Revenue in HKD (TTM)7.86bn
- Net income in HKD-1.38bn
- Incorporated2015
- Employees7.28k
- LocationGenscript Biotech CorpNo. 28Yongxi Road, Jiangning Science ParkNANJING ChinaCHN
- Phone+86 2 558897288
- Fax+86 2 558897288
- Websitehttps://www.genscript.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laekna Inc | 0.00 | -317.46m | 5.19bn | 92.00 | -- | 7.14 | -- | -- | -0.8909 | -0.8909 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 220.30m | -78.01m | 5.22bn | 491.00 | -- | 5.31 | 383.59 | 23.68 | -0.0462 | -0.0462 | 0.1323 | 0.5744 | 0.0847 | 1.86 | 1.53 | 513,514.70 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| TYK Medicines Inc | 0.00 | -459.69m | 10.31bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Keymed Biosciences Inc | 87.71m | -798.20m | 11.05bn | 1.12k | -- | 3.90 | -- | 125.98 | -3.05 | -3.05 | 0.3355 | 10.13 | 0.0207 | 0.3115 | 7.74 | 97,782.76 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 970.03m | -387.02m | 13.36bn | 574.00 | -- | 16.21 | -- | 13.78 | -1.34 | -1.34 | 3.33 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,663,856.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Genscript Biotech Corp | 7.86bn | -1.38bn | 22.57bn | 7.28k | -- | 2.38 | -- | 2.87 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,786.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 2.02bn | -250.05m | 39.11bn | 1.54k | -- | 11.34 | -- | 19.40 | -1.11 | -1.11 | 9.11 | 15.47 | 0.5869 | 9.46 | 167.74 | 1,424,964.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 46.73m | 2.20% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 32.34m | 1.52% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 26.60m | 1.25% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 15.04m | 0.71% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2024 | 14.57m | 0.69% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 10.72m | 0.50% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 9.90m | 0.47% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 8.39m | 0.39% |
| Geode Capital Management LLCas of 14 Nov 2024 | 7.66m | 0.36% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 7.37m | 0.35% |
